In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex
PLOS ONE · 18.04.2024 · 19 (4) · e0298577
DOI: 10.1371/journal.pone.0298577 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 18.04.2024. Verfasst von Braulio Josué Méndez-Sotelo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City, Mexico. Hauptthemen laut MEDLINE: Ceftazidime, Stenotrophomonas maltophilia, Boronic Acids. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Infections caused by Stenotrophomonas maltophilia and related species are increasing worldwide. Unfortunately, treatment options are limited, whereas the antimicrobial resistance is increasing.
Methods
We included clinical isolates identified as S . maltophilia by VITEK 2 Compact. Ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, cefiderocol, quinolones, and tetracycline family members were evaluated by broth microdilution method and compared with first-line treatment drugs. Minimum inhibitory concentrations (MICs) were reported for all antibiotics. We sequenced the Whole Genome of cefiderocol resistant strains (CRSs) and annotated their genes associated with cefiderocol resistance (GACR). Presumptive phylogenetic identification employing the 16S marker was performed.
Results
One hundred and one clinical strains were evaluated, sulfamethoxazole and trimethoprim, levofloxacin and minocycline showed susceptibilities of 99.01%, 95.04% and 100% respectively. Ceftazidime was the antibiotic with the highest percentage of resistance in all samples (77.22%). Five strains were resistant to cefiderocol exhibiting MIC values ≥ 2 μg/mL (4.95%). The β-lactamase inhibitors meropenem/vaborbactam and imipenem/relebactam, failed to inhibit S . maltophilia , preserving both MIC 50 and MIC 90 ≥64 μg/mL. Ceftazidime/avibactam restored the activity of ceftazidime decreasing the MIC range. Tigecycline had the lowest MIC range, MIC 50 and MIC 90. Phylogeny based on 16S rRNA allowed to identify to cefiderocol resistant strains as putative species clustered into Stenotrophomonas maltophilia complex (Smc). In these strains, we detected GARCs such as Mutiple Drug Resistance (MDR) efflux pumps, L1-type β-lactamases, iron transporters and type-1 fimbriae.
Conclusion
Antimicrobial resistance to first-line treatment is low. The in vitro activity of new β-lactamase inhibitors against S . maltophilia is poor, but avibactam may be a potential option. Cefiderocol could be considered as a potential new option for multidrug resistant infections. Tetracyclines had the best in vitro activity of all antibiotics evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.
- Infectious Diseases Department, Instituto Nacional de Cancerología, Mexico City, Mexico.
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.
- Centro Nacional de Referencia de Inocuidad y Bioseguridad Agroalimentaria, Servicio Nacional de Sanidad, Inocuidad y Calidad Agroalimentaria (SENASICA), Tecámac, Mexico State, Mexico.
- Programa "Investigadoras e Investigadores por México", Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), Mexico City, Mexico.
- Medicine Faculty, Bacteriology Laboratory, Microbiology and Parasitology Department, Universidad Nacional Autónoma de México, Mexico City, Mexico.
ORCID-Profile: Braulio Josué Méndez-Sotelo, Claudia Adriana Colín-Castro, Luis Esau Lopez Jacome
Zitieren
APA
Méndez-Sotelo, B. J., Delgado-Beltrán, M., Hernández-Durán, M., Colín-Castro, C. A., Esquivel-Bautista, J., Ortega-Oliva, S. A., Ortiz-Álvarez, J., García-Contreras, R., Franco-Cendejas, R., & Lopez Jacome, L. E. (2024). In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. PLOS ONE, 19(4), e0298577. https://doi.org/10.1371/journal.pone.0298577
Vancouver
Méndez-Sotelo BJ, Delgado-Beltrán M, Hernández-Durán M, Colín-Castro CA, Esquivel-Bautista J, Ortega-Oliva SA, et al. In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. PLOS ONE. 2024;19(4):e0298577. doi:10.1371/journal.pone.0298577
BibTeX
@article{MndezSotelo2024,
author = {Méndez-Sotelo, Braulio Josué and Delgado-Beltrán, Mónica and Hernández-Durán, Melissa and Colín-Castro, Claudia Adriana and Esquivel-Bautista, José and Ortega-Oliva, Sandra Angélica and Ortiz-Álvarez, Jossue and García-Contreras, Rodolfo and Franco-Cendejas, Rafael and Lopez Jacome, Luis Esau},
title = {In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {4},
pages = {e0298577},
doi = {10.1371/journal.pone.0298577}
}
EUVIMED